Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, has partnered with the UK government for its inactivated COVID-19 vaccine, VLA2001.   Under the agreement, if vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021. The UK Government then has options over 40 million doses in 2022 and a further 30 million to 90 million doses, in aggregate, across 2023 to 2025. Revenue from thes...